Researchers at the University of Hong Kong have identified a significant correlation between the use of nitrogen-containing bisphosphonates (NBPs) and a reduced risk of Alzheimer’s disease and related dementias.
Published in Alzheimer’s & Dementia, the study of 120,000 patients aged 60 and older indicates that these common osteoporosis drugs may offer neuroprotective benefits.
Clinical Insights for Patients
- The Medication: Nitrogen-containing bisphosphonates (such as alendronate and zoledronate) are standard treatments that prevent bone tissue breakdown to combat osteoporosis.
- The Finding: Patients using these drugs showed a 24% lower risk of developing dementia compared to those on other osteoporosis medications, and a 16% lower risk compared to those on no treatment.
- The Caveat: This is an observational study. While the link is statistically significant, it does not yet prove that the drugs directly cause the lower risk of cognitive decline.
Hong Kong Study Finds 24% Lower Dementia Risk in NBP Users
The research, led by Professor Cheung Ching-lung at the University of Hong Kong’s LKS Faculty of Medicine, with Dr. Sing Chor-wing serving as the study’s first author, analyzed electronic health records spanning from 2005 to 2020.
The study focused on patients with osteoporosis or fragility fractures—breaks resulting from low-trauma events. By comparing NBP users against patients on other osteoporosis regimens, the team identified a 24% reduction in dementia risk, with particularly pronounced benefits observed in women and those who had suffered hip fractures.
The biological rationale for this potential protection lies in the mechanism of action of NBPs. While their primary role is to slow the breakdown of bone tissue, researchers are exploring whether these drugs also influence pathways involved in neurodegeneration.
“Our study provides evidence that NBPs may offer dual benefits in strengthening bones and reducing fracture risk, as well as potentially preventing ADRD,” said Professor Cheung. “Their potential neuroprotective role provides an empirical basis and supports future research on the actual effectiveness of this medication in preventing or delaying cognitive decline associated with ADRD.”
Comparative Data on Dementia Risk
The following table summarizes the comparative risk associations observed by the research team across the patient cohort:
| Comparison Group | Dementia Risk Reduction |
|---|---|
| NBP Users vs. No Medication | 16% lower risk |
| NBP Users vs. Other Osteoporosis Drugs | 24% lower risk |
Addressing the Global Dementia Burden
Dementia affects over 55 million people worldwide, a figure projected to climb to 139 million by 2050. Given the high costs, limited suitability for some patients, and questions about the effectiveness of newly approved Alzheimer’s therapies, the clinical community has shifted focus toward repurposing existing, affordable medications. Because NBPs are already widely prescribed and have an established history of use, they represent a pragmatic target for further clinical trials.
“These findings are significant as they demonstrate a potential approach for reducing dementia risk in a vulnerable population using safe and widely available NBPs,” said Professor Cheung. “In our rapidly aging society, these findings suggest that while waiting for the novel therapies, existing medications can also provide additional protection for high-risk populations.”
Trials Still Needed to Confirm Causal Effect
Future clinical trials are required to confirm if the observed associations represent a direct causal protective effect on brain health.
